Get the Stockscreener App
18.01
8.53%
-1.68
After Hours:
18.01
Evommune Inc stock is traded at $18.01, with a volume of 123.63K.
It is down -8.53% in the last 24 hours and down -7.74% over the past month.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
See More
Previous Close:
$19.69
Open:
$19.27
24h Volume:
123.63K
Relative Volume:
2.94
Market Cap:
$541.70M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-17.76%
1M Performance:
-7.74%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$17.20
$20.85
1-Week Range:
$17.20
$22.56
52-Week Range:
$17.04
$24.03
Evommune Inc Stock (EVMN) Company Profile
Name
Evommune Inc
Sector
Industry
Phone
(650) 223-7745
Address
1841 PAGE MILL RD, PALO ALTO
Compare EVMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
18.01 | 592.23M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-01-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-25 | Initiated | Evercore ISI | Outperform |
| Dec-01-25 | Initiated | Leerink Partners | Outperform |
| Dec-01-25 | Initiated | Morgan Stanley | Overweight |
| Dec-01-25 | Initiated | William Blair | Outperform |
Evommune Inc Stock (EVMN) Latest News
These Bay Area companies are IPO contenders in 2026 - The Business Journals
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update - BioSpace
Evommune, Inc.: Promising Pipeline and Strategic Trials Drive Buy Rating - TipRanks
Evommune, Inc. SEC 10-Q Report - TradingView — Track All Markets
EVMN: Net loss narrowed to $40.6M as license revenue grew and IPO proceeds extended cash runway into 2028 - TradingView — Track All Markets
Evommune (EVMN) Stock Trends and Sentiment 2025 - MarketBeat
Biopharma funding normalizes as 2025 outperforms post-pandemic lows - BioWorld MedTech
Evommune, Inc. (EVMN) analyst ratings, estimates and forecasts - Yahoo Finance UK
Evommune (NYSE:EVMN) Upgraded at Zacks Research - Defense World
Evommune (EVMN) Competitors and Alternatives 2025 - MarketBeat
Evommune (NYSE:EVMN) Research Coverage Started at Evercore ISI - Defense World
Evommune (NYSE:EVMN) Shares See Activity on Sector Research Shift - Kalkine Media
Evommune (NYSE:EVMN) Stock Rating Upgraded by Leerink Partnrs - MarketBeat
Evommune initiated with an Outperform at William Blair - MSN
Evommune initiated with an Overweight at Cantor Fitzgerald - MSN
Evommune, Inc. (EVMN) options chain - Yahoo Finance UK
Evommune, Inc.: Revenue and Earnings Analysts Forecasts Revisions | EVMN | US30054Y1073 - marketscreener.com
Evommune, Inc.: Target Price Consensus and Analysts Recommendations | EVMN | US30054Y1073 - marketscreener.com
Evommune, Inc.: Dividend historical data and projections - marketscreener.com
Evommune, Inc. (NYSE:EVMN) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Evommune (NYSE:EVMN) Coverage Initiated by Analysts at Leerink Partners - MarketBeat
Evommune initiated with an Overweight at Morgan Stanley - MSN
Evercore ISI initiates Evommune stock with Outperform rating on dermatology potential - Investing.com Australia
Evommune, Inc. (EVMN) Options Chain - Yahoo! Finance Canada
Leerink Partners initiates coverage on Evommune stock with Outperform rating By Investing.com - Investing.com South Africa
Evommune, Inc. (EVMN) Stock Forum & Discussion - Yahoo! Finance Canada
Cantor Fitzgerald initiates Evommune stock with Overweight rating By Investing.com - Investing.com South Africa
Evercore ISI initiates Evommune stock with Outperform rating on dermatology potential By Investing.com - Investing.com South Africa
Leerink Partners initiates coverage on Evommune stock with Outperform rating - Investing.com Nigeria
Evommune initiated with an Outperform at Evercore ISI - MSN
Evommune's Skin Disorder Candidate Has 'Blockbuster Commercial Opportunity': Analyst Projects $5 Billion Peak Sales - Benzinga
EVMN Analyst Forecasts - Quiver Quantitative
This Joby Aviation Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday - Benzinga
William Blair Initiates Coverage on Evommune With Outperform Rating - marketscreener.com
Evercore ISI Initiates Coverage on Evommune With Outperform Rating, $40 Price Target - marketscreener.com
Cantor Fitzgerald Initiates Coverage on Evommune With Overweight Rating - marketscreener.com
Cantor Fitzgerald initiates Evommune stock with Overweight rating - Investing.com
Leerink Partners Initiates Coverage on Evommune With Outperform Rating, $42 Price Target - marketscreener.com
Morgan Stanley Initiates Evommune at Overweight With $36 Price Target - marketscreener.com
William Blair initiates coverage on Evommune stock with Outperform rating By Investing.com - Investing.com South Africa
William Blair initiates coverage on Evommune stock with Outperform rating - Investing.com
Promising Outlook for Evommune’s EVO756: Buy Rating Backed by Strong Data and Market Potential - TipRanks
Promising Future for Evommune, Inc. in Inflammatory and Immunology Markets: Buy Rating Justified by Strong Pipeline and Experienced Leadership - TipRanks
Morgan Stanley initiates Evommune stock with Overweight rating on inflammation pipeline - Investing.com Australia
What is the current Price Target and Forecast for Evommune Inc. (EVMN) - Zacks Investment Research
Evommune Inc. (EVMN) Price Book Value - Zacks Investment Research
Why Is Evommune, Inc. (EVMN) Stock Up Today? - Meyka
EVMN: Evommune Inc.Price & Consenus Chart - Zacks Investment Research
Evommune Inc. (EVMN) Price To Cash Flow - Zacks Investment Research
Evommune Inc. (EVMN) Market Cap - Zacks Investment Research
Evommune Inc. (EVMN) Dividend Yield (TTM) - Zacks Investment Research
Evommune Inc Stock (EVMN) Financials Data
There is no financial data for Evommune Inc (EVMN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):